CO2022015018A2 - Métodos y medios para modificar la hemodinámica en infecciones - Google Patents

Métodos y medios para modificar la hemodinámica en infecciones

Info

Publication number
CO2022015018A2
CO2022015018A2 CONC2022/0015018A CO2022015018A CO2022015018A2 CO 2022015018 A2 CO2022015018 A2 CO 2022015018A2 CO 2022015018 A CO2022015018 A CO 2022015018A CO 2022015018 A2 CO2022015018 A2 CO 2022015018A2
Authority
CO
Colombia
Prior art keywords
infection
hemodynamics
infections
modify
methods
Prior art date
Application number
CONC2022/0015018A
Other languages
English (en)
Inventor
Gert Wensvoort
Eric Claassen
Johan Renes
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv filed Critical Biotempt Bv
Publication of CO2022015018A2 publication Critical patent/CO2022015018A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

RESUMEN Se proporciona un método de tratamiento que comprende administrar un péptido AQGV, o un análogo funcional del mismo, a un sujeto humano, en donde el sujeto humano sufre una infección, particularmente una infección respiratoria, más específicamente una infección viral, más en particular una infección por coronavirus, en donde el tratamiento para administrar un péptido AQGV comprende mantener o mejorar la estabilidad hemodinámica en el sujeto humano.
CONC2022/0015018A 2020-04-06 2022-10-21 Métodos y medios para modificar la hemodinámica en infecciones CO2022015018A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005999P 2020-04-06 2020-04-06
US202063045737P 2020-06-29 2020-06-29
US202063085771P 2020-09-30 2020-09-30
PCT/NL2021/050223 WO2021206547A1 (en) 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections

Publications (1)

Publication Number Publication Date
CO2022015018A2 true CO2022015018A2 (es) 2022-10-31

Family

ID=75581581

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015018A CO2022015018A2 (es) 2020-04-06 2022-10-21 Métodos y medios para modificar la hemodinámica en infecciones

Country Status (9)

Country Link
US (1) US20230241155A1 (es)
EP (1) EP4132556A1 (es)
JP (1) JP2023521744A (es)
KR (1) KR20230003495A (es)
AU (1) AU2021252821A1 (es)
CA (1) CA3174852A1 (es)
CO (1) CO2022015018A2 (es)
MX (1) MX2022012506A (es)
WO (1) WO2021206547A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021354766A1 (en) * 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615655B1 (en) * 2003-04-08 2012-02-22 Biotempt B.V. Use of compositions for mucosal and oral administration comprising hcg fragments
MX2022003820A (es) * 2019-09-30 2022-09-19 Ebi Anti Sepsis B V Metodos de tratamiento para modificar la hermodinamica.

Also Published As

Publication number Publication date
WO2021206547A1 (en) 2021-10-14
US20230241155A1 (en) 2023-08-03
EP4132556A1 (en) 2023-02-15
MX2022012506A (es) 2023-01-16
JP2023521744A (ja) 2023-05-25
KR20230003495A (ko) 2023-01-06
CA3174852A1 (en) 2021-10-14
AU2021252821A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
DOP2023000187A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
PH12020500555A1 (en) Esketamine for the treatment of depression
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
MX2021014771A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
CO2022015018A2 (es) Métodos y medios para modificar la hemodinámica en infecciones
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
CL2022000786A1 (es) Metodos de tratamiento para modificar la hemodinamica
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2022003134A (es) Administracion intranasal de esketamina.
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
ATE415973T1 (de) Gemeinsame gabe von tigecyclin und digoxin
CL2023002914A1 (es) Dosificación y administración de l-asparaginasa recombinante
CO2023007851A2 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos
ZA202206123B (en) Methods of treating hiv-1 infection
CL2022001079A1 (es) Métodos y composiciones para el tratamiento del síndrome de rett
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
MX2022013722A (es) Cisteamina para el tratamiento de infección por sars-cov-2.
WO2022043273A3 (en) Oral care composition comprising a fructanase
MX2022012001A (es) Tratamiento preventivo de la migra?a.
JP1735110S (ja) 医療用電極
JP1735109S (ja) 医療用電極